Biography
Ashley's work at GeneDx is focused on expanding access to NGS diagnostics for pediatric rare disease. With 15 years of experience in healthcare, Ashley previously held positions in sales, marketing, and market access at leading U.S. pharmaceutical companies and clinical laboratories, such as Illumina, AstraZeneca, Counsyl (now Myriad Women's Health), and Invitae. Her unique background brings an understanding of the challenges facing stakeholders in the implementation of personalized medicine. Being part of a family impacted by rare disease, Ashley has a deeply personal passion for making personalized medicine part of routine clinical care.
Talk
Sharing Insights: Payer Coverage of Pediatric Exome and Genome
Payer coverage is vital for personalized medicine to become part of routine clinical care. Over the last 5 years, payer coverage of NGS testing has grown tremendously. We will take a look at where coverage stands today and where it is moving in the years to come.
Track Chair:
Ed Esplin, Invitae
Genetic testing has evolved over time and various applications have successfully made it into the clinical setting. While oncology applications are dominating, we also see a rise in genetic/genomic applications for reproductive health, CVD diagnosis, or early life understanding. Technological advancements are required to scale genetic testing applications delivery including relay of genomic information to clinicians and patients. In parallel to technological challenges, hurdles are also observed when it comes to insight/knowledge extraction, reporting of clinical findings, and scaling of genetic counseling. This track will touch upon these various aspects including successful precision medicine models through biopharma ventures for rare disease understanding and direct to consumer genetic testing.
Sessions: